


# PRODUCT INFORMATION



## Zanubrutinib

Item No. 28924

**CAS Registry No.:** 1691249-45-2  
**Formal Name:** (7S)-4,5,6,7-tetrahydro-7-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)-pyrazolo[1,5-a]pyrimidine-3-carboxamide  
**Synonym:** BGB-3111  
**MF:** C<sub>27</sub>H<sub>29</sub>N<sub>5</sub>O<sub>3</sub>  
**FW:** 471.6  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 242 nm  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Zanubrutinib is supplied as a solid. A stock solution may be made by dissolving the zanubrutinib in the solvent of choice, which should be purged with an inert gas. Zanubrutinib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of zanubrutinib in ethanol and DMSO is approximately 5 mg/ml and approximately 10 mg/ml in DMF.

Zanubrutinib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, zanubrutinib should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Zanubrutinib has a solubility of approximately 0.16 mg/ml in a 1:5 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Zanubrutinib is a potent and covalent inhibitor of Bruton's tyrosine kinase (BTK; IC<sub>50</sub> = 0.3 nM).<sup>1</sup> It is selective for BTK over a panel of 304 kinases at 1 μM but does inhibit EGFR, Tec, Blk, BMX, HER4, and TXK (IC<sub>50</sub>s = 0.62-33 nM). Zanubrutinib inhibits phosphorylation of BTK at Y233 (IC<sub>50</sub> = 1.8 nM) in Ramos cells and reduces viability of Rec-1 cells (IC<sub>50</sub> = 0.36 nM). *In vivo*, zanubrutinib (2.5 and 7.5 mg/kg) reduces tumor volume in an OCI-LY10 diffuse large B cell lymphoma (DLBCL) mouse xenograft model.

### Reference

1. Guo, Y., Liu, Y., Hu, N., *et al.* Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of bruton's tyrosine kinase. *J. Med. Chem.* **62**(17), 7923-7940 (2019).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/08/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM